Expression of MicroRNA-9 is Associated With Overall Survival in Breast Cancer Patients.

BACKGROUND

MicroRNA-9 (miR-9) was found to play an important role in a variety of different cancers and can adopt either tumor suppressor or oncogenic activity. Most studies have suggested an oncogenic role in breast cancer. We were interested in the relationship of miR-9 expression and survival in breast cancer and hypothesized that high expression of miR-9 was associated with worse prognosis in breast cancer patients.

MATERIALS AND METHODS

We utilized The Cancer Genome Atlas containing genetic and molecular data, clinical profiles, and survival information for 985 breast cancers. Survival analysis was performed comparing a group with low expression of miR-9 to a group with high expression. Expression of miR-9 was compared based on clinicopathological parameters. Gene set enrichment analysis was performed between the miR-9 high- and low-expression groups within the estrogen receptor (ER)-positive cohort.

RESULTS

Low expression of miR-9 associated significantly with improved overall survival (OS) (P = 0.003). There was no significant difference in miR-9 expression with regard to disease-free survival. Smaller and early-stage tumors were associated with lower miR-9 expression. ER-positive breast cancers had lower levels of miR-9 than ER-negative breast cancers (P < 0.001), and within the ER-positive group, miR-9 expression was significantly associated with OS (P = 0.02). Gene set enrichment analysis showed enrichment of estrogen response genes in the miR-9 low-expression group.

CONCLUSIONS

Low miR-9 expression appeared to have a protective effect and was associated with improved OS, smaller tumors, earlier stage, and ER-positive cancers due to enrichment of estrogen response genes.